DOCSLIB.ORG

Combined Index to USP 42 and NF 37, Volumes 1–5, Including Second Supplement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Index to USP 42 and NF 37, Volumes 1–5, Including Second Supplement Combined Index to USP 42 and NF 37 Abaca-Aceto I-1 Combined Index to USP 42 and NF 37, Volumes 1±5, including Second Supplement Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 42±NF 37 and its First and Second Supplement. This index is repeated in its entirety in each volume. 1±2430 Volume 1 2431±4680 Volume 2 4681±6046 Volume 3 6047±7104 Volume 4 7105±8582 Volume 5 8583±9055 First Supplement 9057±9678 Second Supplement Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. butalbital and caffeine tablets, 630 and pentazocine tablets, 3433 A and caffeine tablets, 52 and pseudoephedrine hydrochloride capsules, 42 tablets, 73 Abacavir and (salts of) chlorpheniramine, oral solution, 43 oral solution, 21 dextromethorphan, and for effervescent oral solution, 44 sulfate, 25 pseudoephedrine, capsules containing at suppositories, 44 tablets, 22 least three of the following, 53 oral suspension, 45, 8619 and lamivudine tablets, 23 and (salts of) chlorpheniramine, tablets, 47 Abiraterone dextromethorphan, and extended-release tablets, 48 acetate, 27 pseudoephedrine, oral powder and tramadol hydrochloride oral acetate tablets, 28 containing at least three of the suspension, 4415 Absolute following, 55 Acetanilide, 6070 alcohol, 6071 and (salts of) chlorpheniramine, Acetate ether, 6070 dextromethorphan, and methyl, 6116 Absorbable pseudoephedrine, oral solution Acetate buffer, 6083 dusting powder, 1538 containing at least three of the TS, 6164 gelatin film, 2045 following, 58 Acetazolamide, 75, 8621 gelatin sponge, 2045 and (salts of) chlorpheniramine, for injection, 75 surgical suture, 4148, 9261 dextromethorphan, and oral suspension, 77 Absorbent pseudoephedrine, tablets containing at tablets, 78 cotton, 6070 least three of the following, 60 Acetic acid, 5553, 6070 gauze, 2043 chlorpheniramine maleate, and ammonium acetate buffer TS, 6164 Acacia, 5551 dextromethorphan hydrobromide diluted, 5553, 6070, 6098 syrup, 5551 tablets, 62 double-normal (2 N), 6177 Acamprosate calcium, 30 and codeine phosphate capsules, 64 glacial, 78, 6070, 6107 Acarbose, 32 and codeine phosphate oral solution, 65 glacial, TS, 6164, 6168 tablets, 33 and codeine phosphate oral suspension, and hydrocortisone otic solution, 2185 Acebutolol hydrochloride, 35 66 irrigation, 79 capsules, 37 and codeine phosphate tablets, 68 metaphosphoric, TS, 6170 Acepromazine maleate, 38 dextromethorphan hydrobromide, otic solution, 79 injection, 39 doxylamine succinate, and strong, TS, 6164 tablets, 40 pseudoephedrine hydrochloride oral 1 M TS, 6164 Acesulfame potassium, 5552 solution, 69 2 M TS, 6164 Acetal, 6070 and diphenhydramine citrate tablets, 71 Acetic acid in peptides, 6669 Acetaldehyde, 6070 diphenhydramine hydrochloride, and 0.008 M Acetic acid TS, 6164 TS, 6164 pseudoephedrine hydrochloride tablets, 0.3 N Acetic acid TS, 6164 Acetaldehyde ammonia trimer trihydrate, 72 Acetic anhydride, 6070 6070 and hydrocodone bitartrate tablets, 2176 Acetohydroxamic acid, 80 Acetaminophen, 40 isometheptene mucate, and tablets, 81 aspirin and caffeine tablets, 51 dichloralphenazone capsules, 2377 Acetone, 5554, 6070 and aspirin tablets, 49 and oxycodone capsules, 3313 anhydrous, 6070 butalbital and caffeine capsules, 629 and oxycodone tablets, 3315 neutralized, 6070, 6164, 6166 I-2 Aceto-Alumi Combined Index to USP 42 and NF 37 Acetonitrile, 6070 Inhalation and nasal drug products: Alfentanil spectrophotometric, 6070 aerosols, sprays, and powdersÐ hydrochloride, 123 Acetophenone, 6070 performance quality tests 〈601〉, 6746 injection, 124 p-Acetotoluidide, 6070 Isoproterenol sulfate inhalation, 2388 Alfuzosin hydrochloride, 125 Acetylacetone, 6070 Lidocaine topical, 2568 extended-release tablets, 126 Acetyl chloride, 6070 Polymyxin B sulfate and bacitracin zinc Alginates assay 〈311〉, 6589 Acetylcholine chloride, 82, 6071 topical, 3564 Alginic acid, 5562 for ophthalmic solution, 82 Povidone±iodine topical, 3607 Alizarin complexone, 6072 Acetylcysteine, 83 Thimerosal topical, 4310 Alkaline Acetylcysteine Tolnaftate topical, 4390 cupric citrate TS, 6164 compounded solution, 84 Triamcinolone acetonide topical, 4445 cupric citrate TS 2, 6164 and isoproterenol hydrochloride inhalation cupric iodide TS, 6164 solution, 85 mercuric-potassium iodide TS, 6164 solution, 84 phosphatase enzyme, 6072 N-Acetylglucosamine, 4701 Agar, 5557, 6071 picrate TS, 6164 2-Acetylresorcinol, 8882 Agarose, 6071 pyrogallol TS, 6173 3-Acetylthio-2-methylpropanoic acid, 6071 Air, medical, 101 sodium hydrosulfite TS, 6164 Acetyltributyl citrate, 5555 Air-helium certified standard, 6071 Alkaline borate buffer, 6083 Acetyltriethyl citrate, 5555 Alanine, 102, 4704 Alkaline cupric tartrate TS, 6164 N-Acetyltyrosine, 4702 L-Alanyl-L-glutamine, 4704 Alkyl (C12-15) benzoate, 5563 N-Acetyl-L-tyrosine ethyl ester, 6071 Albendazole, 103 Alkylphenoxypolyethoxyethanol, 6072 Acid oral suspension, 103 Allantoin, 131 acrylic, 6071 tablets, 104 Allopurinol, 132 alpha lipoic, 5066 Albumen TS, 6164 oral suspension, 134 dehydroacetic, 5694 Albumin tablets, 134 ferric chloride TS, 6164 bovine serum, 6071 Allyl isothiocyanate, 135 ferrous sulfate TS, 6164 human, 105 Almond oil, 5563 Folic, compounded oral soultion, 1980 rAlbumin human, 5558 Almotriptan iminodiacetic, 6111 Albuterol, 105 tablets, 138 stannous chloride TS, 6164 sulfate, 110 Almotriptan malate, 136 stannous chloride TS, stronger, 6164 tablets, 106 Aloe, 140 Acid-neutralizing capacity 〈301〉, 6588 extended-release tablets, 107 Alosetron Acidulated phosphate and sodium fluoride Alclometasone dipropionate, 111 tablets, 9094 topical solution, 4036 cream, 112 Alosetron hydrochloride, 9093 Acitretin, 86 ointment, 113 Alpha capsules, 87 Alcohol, 114, 6071 lipoic acid, 5066 Statistical tools for procedure validation 70 percent, 80 percent, and 90 percent, Alpha-chymotrypsin, 6072 〈1210〉, 7126, 7524, 7998 6071 Alpha cyclodextrin hydrate, 6072 Acrylic acid, 6071 absolute, 6071 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Activated aldehyde-free, 6072 6072 alumina, 6071 alpha-(2-(methylamino)ethyl)benzyl, 6072 Alphanaphthol, 6072 charcoal, 905, 6071 amyl, 6072 Alphazurine 2G, 6158 magnesium silicate, 6071 tert-amyl, 6072, 6075, 6112 Alprazolam, 141 Acyclovir, 89 butyl, 5602 oral suspension, 142 capsules, 90 dehydrated, 116, 6072, 6093 tablets, 143 for injection, 91 dehydrated isopropyl, 6072 extended-release tablets, 145 ointment, 92 denaturated, 6072 orally disintegrating tablets, 149 oral suspension, 93 denaturated, TS, 6167 Alprenolol hydrochloride, 6072 tablets, 94 determination 〈611〉, 6776 Alprostadil, 151 Adamantane, 6071 in dextrose injection, 118 injection, 153 Adapalene, 95 diluted, 5560, 6072 Alteplase, 154 gel, 97 injection, dehydrated, 117 for injection, 157 Ademetionine disulfate tosylate, 4703 isobutyl, 6072 Alternative microbiological sampling methods Adenine, 98 isopropyl, 6072 for nonsterile inhaled and nasal products sulfate, 6071 methyl, 6072 〈610〉, 6774 Adenosine, 99 neutralized, 6072, 6121 Altretamine, 160 injection, 100 phenol TS, 6164 capsules, 161 Adipic acid, 5556, 6071 n-propyl, 6072 Alum, 6072, 6073 Admissions rubbing, 119 ammonium, 162, 6073 to NF 37, 5538, 8606, 9080 secondary butyl, 6072 potassium, 163, 6131 to USP 42, xxxi, 8598, 9072 tertiary butyl, 6072 Alumina, 6073 Alcoholic activated, 6071, 6073, 6076 ammonia TS, 6164 anhydrous, 6073 mercuric bromide TS, 6164 aspirin, codeine phosphate, and magnesia potassium hydroxide TS, 6164 tablets, 398 Aerosol potassium hydroxide TS 2, 6173 aspirin, and magnesia tablets, 391 Bacitracin and polymyxin B sulfate topical, TS, 6164 aspirin, and magnesium oxide tablets, 393 460 Alcoholic potassium hydroxide magnesia, and calcium carbonate Benzocaine, butamben, and tetracaine 0.2 N VS, 6177 chewable tablets, 167 hydrochloride topical, 506 Alcoholometric table, 6284 magnesia, calcium carbonate, and Benzocaine and menthol topical, 511 Aldehyde dehydrogenase, 6072 simethicone chewable tablets, 168 Benzocaine topical, 496 Alendronate sodium, 120 magnesia, and calcium carbonate oral Fluticasone propionate and salmeterol tablets, 121 suspension, 165 inhalation, 1960 Alfadex, 5561 magnesia, and simethicone oral Fluticasone propionate inhalation, 1943 suspension, 170 Combined Index to USP 42 and NF 37 Alumi-Ammon I-3 Alumina (continued) Amaranth, 6073 Aminosalicylate sodium, 247, 8635 magnesia, and simethicone chewable TS, 6164 tablets, 248, 8637 tablets, 172 Amcinonide, 208, 8629 Aminosalicylic acid, 250 and magnesia oral suspension, 164 cream, 209, 9096 tablets, 251, 8638 and magnesia tablets, 165 ointment, 210, 8629 3-Aminosalicylic acid, 6074 magnesium carbonate, and magnesium American ginseng, 4706 Amiodarone oxide tablets, 175 capsules, 4710 hydrochloride injection, 254, 9097 and magnesium carbonate oral suspension, extract, powdered, 4709 Amiodarone hydrochloride, 253 173 powdered, 4708 oral suspension, 256 and magnesium carbonate tablets, 174 tablets, 4713 Amiodarone hydrochloride and magnesium trisilicate oral suspension, Amifostine, 210 tablets, 9099 176 for injection, 211 Amitraz, 257 and magnesium trisilicate tablets, 177 Amikacin, 213 concentrate for dip, 258 Aluminon, 6073 sulfate, 214 Amitriptyline hydrochloride, 259 Aluminum, 6073 sulfate injection, 215 and chlordiazepoxide tablets, 919 acetate topical solution, 178 Amiloride hydrochloride, 216 and perphenazine tablets, 3460 chloride, 178 and hydrochlorothiazide tablets, 218, 8630 tablets, 261 chlorohydrate, 179 tablets, 216 Amlodipine chlorohydrate solution, 180 Amiloxate, 220 oral suspension,
Load more

Recommended publications
  • Dudley Chemical Corporation
    Dudley Chemical 125 Kenyon Drive Lakewood NJ 08701 Corporation (732) 886-3100 • Fax: 732-886-3688 Indicators Code Product CAS Number 02793 Alizarin Complexone 2 Hydrate 3952-78-1 02861 Alizarin Yellow GG 584-42-9 08137 Bromochlorophenol Blue Sodium Salt 102185-52-4 08142 Bromocresol Green Free Acid ACS 76-60-8 08146 Bromocresol Green Sodium Salt ACS 62625-32-5 08152 Bromocresol Purple Free Acid ACS 115-40-2 08156 Bromocresol Purple Sodium Salt ACS 62625-30-3 08162 Bromophenol Blue Free Acid ACS 115-39-9 08166 Bromophenol Blue Sodium Salt ACS 62625-28-9 08168 Bromopyrogallol Red 16574-43-9 08172 Bromothymol Blue Free Acid ACS 76-59-5 08176 Bromothymol Blue Sodium Salt ACS 34722-90-2 08440 Bromophenol Red Free Acid 2800-80-8 08443 Bromophenol Red Sodium Salt 102185-50-2 08490 Bromoxylenol Blue 40070-59-5 09268 Calconcarboxylic Acid 3737-95-9 09330 Calmagite 3147-14-6 09798 Chlorophenol Red 4430-20-0 09801 Chlorophenol Red 4430-20-0 09803 Chlorophenol Red Sodium Salt 123333-64-2 11100 Congo Red 573-58-0 12100 o-Cresolphthalein 596-27-0 12103 o-Cresolphthalein Complexone 2411-89-4 12106 o-Cresolphthalein Compexone Sodium Salt 94442-10-1 12131 Meta-Cresol Purple Free Acid 2303-01-7 12135 meta-Cresol Purple W/S 62625-31-4 12152 Cresol Red Free acid 1733-12-6 12157 Cresol Red Sodium Salt 62625-29-0 20320 Eriochrome Blue Black R 2538-85-4 20507 Ethyl Orange Sodium Salt 62758-12-7 20582 Ethyl Red Indicator 76058-33-8 21140 Fast Sulphon Black F 3682-47-1 Dudley Chemical Corporation • Indicators, Page 1 of 5 23701 Fluorexon / Calcein 1461-15-0 34024
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Topical Budesonide for Treating Giant Rectal Pseudopolyposis
    ANTICANCER RESEARCH 25: 2961-2964 (2005) Topical Budesonide for Treating Giant Rectal Pseudopolyposis CHARALAMPOS PILICHOS1, ATHENA PREZA1, MARIA DEMONAKOU2, DIMITRIOS KAPATSORIS1 and CONSTANTINOS BOURAS1 1First Department of Internal Medicine and 2Department of Pathology, Sismanogleion Hospital, Athens, Greece Abstract. Pseudopolyps are a frequent finding in the course of Case Report inflammatory bowel disease. They are non-neoplastic lesions resulting from a regenerative and healing process that leaves A 45-year-old male patient was admitted to our service in July inflamed colonic mucosa in polypoid configuration. Data about 2002 for acute rectal bleeding. All laboratory tests were their management is lacking. "Giant" pseudopolyps can be normal, except an increase of aminotransferases level (>10 N) mistaken for adenocarcinomas and, as they rarely regress with and a serological profile consistent with acute hepatitis B or a medical management alone, a surgical resection is often required. flare of chronic hepatitis B (HbsAg +, HbsAb –, HbeAg –, A case of giant pseudopolyposis treated non-surgically, in a patient HbeAb +, HbcAb-IgM +). The patient underwent lower with concomitant ulcerative colitis and chronic hepatitis B, is gastro-intestinal endoscopy and multiple biopsies were taken reported, representing a co-morbidity complicating an eventual from a bulky rectal mass lesion (Figure 1). Histological study conservative treatment. The clinical implementation of topical revealed alterations compatible with inflammatory bowel budesonide was originally tested, resulting in clinical, endoscopic disease (IBD) with no dysplasia (Figure 2). Because of the and histological remission. Budesonide seems a promising therapy atypical macroscopic features and the high suspicion of rectal for IBD, particularly when a comorbidity with viral hepatitis exist.
    [Show full text]
  • Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D
    PRACTICE PARAMETERS Practice Parameters for the Surgical Treatment of Ulcerative Colitis Howard Ross, M.D. • Scott R. Steele, M.D. • Mika Varma, M.D. • Sharon Dykes, M.D. Robert Cima, M.D. • W. Donald Buie, M.D. • Janice Rafferty, M.D. Prepared by the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons the most common surgical indication for UC. Whether is dedicated to assuring high-quality patient care it is secondary to an inability to control symptoms, poor Tby advancing the science, prevention, and manage- quality of life, risks/side effects of chronic medical therapy ment of disorders and diseases of the colon, rectum, and (especially long-term corticosteroids), noncompliance, or anus. The Standards Committee is composed of Society growth failure, patients may opt for surgery in the elective members who are chosen because they have demonstrat- or semielective setting.3 Complete removal of all the poten- ed expertise in the specialty of colon and rectal surgery. tial disease-bearing tissue is theoretically curative in UC. This Committee was created to lead international efforts Operative options include an abdominal colectomy or total in defining quality care for conditions related to the co- proctocolectomy with either a permanent end ileostomy or lon, rectum, and anus. This is accompanied by develop- surgical construction of a “new” rectum through an IPAA ing Clinical Practice Guidelines based on the best available that restores GI continuity.4,5 All these procedures may evidence. These guidelines are inclusive, and not prescrip- be performed by using open or minimally invasive tech- tive.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Alphabetical Listing by Therapeutic Category GOODFELLOW AFB ROSS CLINIC FORMULARY
    GOODFELLOW AFB ROSS CLINIC FORMULARY Alphabetical Listing by Therapeutic Category This document is current as of October 8, 2020. The availability of formulary items is subject to change. ACARBOSE Acarbose ALPRAZolam Outpatient Dosage Forms Outpatient Formulary Brands Available Xanax Tablet, Oral: Outpatient Dosage Forms Generic: 25 mg, 50 mg, 100 mg Tablet, Oral: Xanax: 0.5 mg, 1 mg [scored] Acetaminophen Generic: 0.5 mg, 1 mg Outpatient Formulary Brands Available Mapap Children's [OTC]; Mapap [OTC] Aluminum Chloride Hexahydrate Outpatient Dosage Forms Outpatient Formulary Brands Available Drysol Suspension, Oral: Outpatient Dosage Forms Mapap Children's: 160 mg/5 mL (118 mL) [ethanol free; contains propylene Solution, External: glycol, sodium benzoate; cherry flavor] Drysol: 20% (60 mL) Tablet, Oral: Mapap: 325 mg Aluminum Hydroxide, Magnesium Hydroxide, and Simethicone Generic: 325 mg Outpatient Dosage Forms Liquid, Oral: Acetaminophen and Codeine Generic: Aluminum hydroxide 200 mg, magnesium hydroxide 200 mg, and Outpatient Dosage Forms simethicone 20 mg per 5 mL (360 mL) Solution, Oral [C-V]: Generic: Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL Amantadine (118 mL) [BCF] Outpatient Dosage Forms Tablet, Oral [C-III]: Capsule, Oral, as hydrochloride: Generic: Acetaminophen 300 mg and codeine phosphate 30 mg [BCF] Generic: 100 mg [BCF] AcetaZOLAMIDE Amiodarone Outpatient Dosage Forms Outpatient Dosage Forms Tablet, Oral: Tablet, Oral, as hydrochloride: Generic: 250 mg Generic: 200 mg [BCF] Acetic Acid, Propylene Glycol Diacetate,
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • US EPA Inert (Other) Pesticide Ingredients
    U.S. Environmental Protection Agency Office of Pesticide Programs List of Inert Pesticide Ingredients List 3 - Inerts of unknown toxicity - By Chemical Name UpdatedAugust 2004 Inert Ingredients Ordered Alphabetically by Chemical Name - List 3 Updated August 2004 CAS PREFIX NAME List No. 6798-76-1 Abietic acid, zinc salt 3 14351-66-7 Abietic acids, sodium salts 3 123-86-4 Acetic acid, butyl ester 3 108419-35-8 Acetic acid, C11-14 branched, alkyl ester 3 90438-79-2 Acetic acid, C6-8-branched alkyl esters 3 108419-32-5 Acetic acid, C7-9 branched, alkyl ester C8-rich 3 2016-56-0 Acetic acid, dodecylamine salt 3 110-19-0 Acetic acid, isobutyl ester 3 141-97-9 Acetoacetic acid, ethyl ester 3 93-08-3 2'- Acetonaphthone 3 67-64-1 Acetone 3 828-00-2 6- Acetoxy-2,4-dimethyl-m-dioxane 3 32388-55-9 Acetyl cedrene 3 1506-02-1 6- Acetyl-1,1,2,4,4,7-hexamethyl tetralin 3 21145-77-7 Acetyl-1,1,3,4,4,6-hexamethyltetralin 3 61788-48-5 Acetylated lanolin 3 74-86-2 Acetylene 3 141754-64-5 Acrylic acid, isopropanol telomer, ammonium salt 3 25136-75-8 Acrylic acid, polymer with acrylamide and diallyldimethylam 3 25084-90-6 Acrylic acid, t-butyl ester, polymer with ethylene 3 25036-25-3 Acrylonitrile-methyl methacrylate-vinylidene chloride copoly 3 1406-16-2 Activated ergosterol 3 124-04-9 Adipic acid 3 9010-89-3 Adipic acid, polymer with diethylene glycol 3 9002-18-0 Agar 3 61791-56-8 beta- Alanine, N-(2-carboxyethyl)-, N-tallow alkyl derivs., disodium3 14960-06-6 beta- Alanine, N-(2-carboxyethyl)-N-dodecyl-, monosodium salt 3 Alanine, N-coco alkyl derivs.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]